Patent ID: 6468976
Filing Date: 2002-10-22
Classification: A61K,C07K

Abstract:
A method of inhibiting angiotensin converting enzyme comprising administering to a subject suffering from hypertension, congestive heart failure, acute myocardial infarction or renal or retinal complications of diabetes mellitus a composition comprising a lisinopril monohydrate formed by the process consisting of:(a) dissolving lisinopril (1-(N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl)-L-proline) in water to form a solution; (b) adding isobutanol to the solution of step (a) in an amount and under conditions effective to induce crystallisation of the lisinopril; (c) isolating the crystals formed in step (b); (d) drying the crystals at a temperature not to exceed 80Â° C. for a time and under conditions effective to produce particulate crystalline lisinopril monohydrate; and (e) recovering the crystalline lisinopril monohydrate, wherein the administration is for a time and under conditions effective to inhibit angiotensin converting enzyme.